arm1: The right peptides (up to 4 peptides) for vaccination to individual patients will be selected in consideration of the pre-existing host immunity assessed by the titers of anti-peptide IgG befo
Sponsors
Kurume University Cancer Vaccine Center
Conditions
colorectal cancergastric cancerlung cancer
Phase 2
Phase II randomised clinical trial of personalized peptide vaccination in combination with Dai-kenchu-to for colorectal cancer patients resistant to standard therapies.
Active, not recruitingJPRN-UMIN000008126
Start: 2012-06-04Target: 60Updated: 2026-06-29
Phase II randomised clinical trial of personalized peptide vaccination in combination with Juzen-taiho-to for gastric cancer patients resistant to standard therapies .
Active, not recruitingJPRN-UMIN000008827
Start: 2012-09-01Target: 60Updated: 2026-06-29
Phase II randomised clinical trial of personalized peptide vaccination in combination with Ninjin-yoei-to for lung cancer patients resistant to standard therapies .
Active, not recruitingJPRN-UMIN000008940
Start: 2012-09-19Target: 80Updated: 2026-06-29